Scientists at Michigan Medicine have made a significant breakthrough in treating nonalcoholic fatty liver disease (NAFLD), a ...

Nonalcoholic steatohepatitis (NASH) is the progressive form of liver injury that carries a risk for progressive fibrosis, cirrhosis, and end-stage liver disease. Hepatocellular carcinoma (HCC ...

NASH is a form of non-alcoholic fatty liver disease (NAFLD) that affects millions of people and which, for several years, has been billed as pharma's next big growth area. Although, so far efforts ...

Watch what you eat. Fatty buildup in your liver can cause nonalcoholic steatohepatitis and lead to cirrhosis. NASH is linked to high cholesterol, coronary artery disease, obesity, and diabetes.

Where multiple sensitivity and specificity values are reported, the values providing the highest Youden Index are given (i.e., highest sum of sensitivity and specificity minus one). ALT: Alanine ...

A study from Massachusetts General Hospital has found that growth hormone may help improve liver health in people with ...

One of these is non-alcoholic steatohepatitis, or NASH, the fatty liver disease that affects millions of people and which is poised to be one of pharma’s next big growth areas. Novartis ramped ...

Since symptoms don’t appear until the condition worsens, the only way to detect fatty liver early is through blood tests (LFT ...

MASH is a type of nonalcoholic liver disease. (It used to be known as nonalcoholic steatohepatitis, or NASH). MASH happens when fat builds up in your liver, but it's not from alcohol use.